CCL21 and mantle cell lymphoma: Although the number of MCL cells migrating in response to CCL21 differed greatly between patients, pre-treatment with duvelisib significantly and substantially (> 40%) inhibited MCL lymphocyte migration in every case [n = 6; Fig. 4B and Supplementary Figure 4D; (P = 0.02)].